COST-EFFECTIVENESS OF TREMELIMUMAB PLUS DURVALUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Xiong, X. [1 ]
Guo, J. J. [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] Univ Cincinnati, Plain City, OH USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE520
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Yang, Yang
    Feng, Mingyang
    Lei, Wanting
    Bai, Liangliang
    Li, Junying
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [2] Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
    Xiong, Xiaomo
    Guo, Jeff Jianfei
    PHARMACOECONOMICS, 2025, 43 (03) : 271 - 282
  • [3] First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
    Fujii, Yasutoshi
    Kawaoka, Tomokazu
    Shirane, Yuki
    Miura, Ryoichi
    Nakahara, Hikaru
    Yamaoka, Kenji
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Murakami, Eisuke
    Miki, Daiki
    Hayes, Nelson Clair
    Tsuge, Masataka
    Nakamura, Yuko
    Awai, Kazuo
    Oka, Shiro
    ONCOLOGY, 2024,
  • [4] COST-EFFECTIVENESS OF TREMELIMUMAB OR TREMELIMUMAB IN COMBINATION WITH DURVALUMAB VS DURVALUMAB AS TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
    Tang, T.
    Shi, L.
    VALUE IN HEALTH, 2023, 26 (06) : S138 - S138
  • [5] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Guan, Haijing
    Wang, Chunping
    Zhao, Zhigang
    Han, Sheng
    ADVANCES IN THERAPY, 2022, 39 (07) : 3334 - 3346
  • [6] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Haijing Guan
    Chunping Wang
    Zhigang Zhao
    Sheng Han
    Advances in Therapy, 2022, 39 : 3334 - 3346
  • [7] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
    Zou, Huimin
    Lai, Yunfeng
    Chen, Xianwen
    Ung, Carolina Oi Lam
    Hu, Hao
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [8] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [9] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
  • [10] First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wang, Liting
    Peng, Ye
    Qin, Shuxia
    Wan, Xiaomin
    Zeng, Xiaohui
    Li, Sini
    Liu, Qiao
    Tan, Chongqing
    PLOS ONE, 2023, 18 (04):
12345